• International Stem Cell’s board, acting by unanimous written consent on July 10, 2026, cleared a sale of its Lifeline Cell Technology unit.
• Transaction calls for selling 100% of Lifeline Cell Technology membership interests to ATCC for USD 25 million, subject to working-capital, cash, debt adjustments.
• ATCC to pay cash at closing, withholding USD 2.5 million for an indemnity escrow, USD 100,000 for an adjustment escrow.
• Board also authorized execution of the purchase agreement and related documents, submitting the deal for stockholder approval by written consent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005946), on August 04, 2026, and is solely responsible for the information contained therein.